Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.

Anaplastic large cell lymphoma (ALCL) is a distinct entity of T-cell lymphoma that can be divided into 2 subtypes based on the presence of translocations involving the ALK gene (ALK(+) and ALK(-) ALCL). The interferon regulatory factor 4 (IRF4) is known to be highly expressed in both ALK(+) and ALK(-) ALCLs. However, the role of IRF4 in the pathogenesis of these lymphomas remains unclear. Here we show that ALCLs of both subtypes are addicted to IRF4 signaling, as knockdown of IRF4 by RNA interference was toxic to ALCL cell lines in vitro and in ALCL xenograft mouse models in vivo. Gene expression profiling after IRF4 knockdown demonstrated a significant downregulation of a variety of known MYC target genes. Furthermore, our analyses revealed that MYC is a primary target of IRF4, identifying a novel regulatory mechanism of MYC expression and its target gene network in ALCL. MYC, itself, is essential for ALCL survival, as both knockdown of MYC and pharmacologic inhibition of MYC signaling were toxic to ALCL cell lines. Collectively, our results demonstrate that ALCLs are dependent on IRF4 and MYC signaling and that MYC may represent a promising target for future therapies.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  M. Huber,et al.  IRF4 at the crossroads of effector T‐cell fate decision , 2014, European journal of immunology.

[3]  J. Tobias,et al.  Malignant Transformation of CD4+ T Lymphocytes Mediated by Oncogenic Kinase NPM/ALK Recapitulates IL-2–Induced Cell Signaling and Gene Expression Reprogramming , 2013, The Journal of Immunology.

[4]  A. Rosenwald,et al.  PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. , 2013, Blood.

[5]  G. Lenz,et al.  I{kappa}B-{zeta} controls the constitutive NF-{kappa}B target gene network and survival of ABC DLBCL , 2013 .

[6]  G. Lenz,et al.  PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[7]  L. Meltesen,et al.  Dual ALK and MYC Rearrangements Leading to an Aggressive Variant of Anaplastic Large Cell Lymphoma , 2013, Journal of pediatric hematology/oncology.

[8]  G. Lenz,et al.  MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma , 2013, Leukemia.

[9]  T. Witzig,et al.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. , 2012, Blood.

[10]  S. Rutz,et al.  A Genomic Regulatory Element That Directs Assembly and Function of Immune-Specific AP-1–IRF Complexes , 2012, Science.

[11]  P. Gaulard,et al.  Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Lu Wang,et al.  BATF-JUN is critical for IRF4-mediated transcription in T cells , 2012, Nature.

[13]  Michael S. Behnke,et al.  Compensatory dendritic cell development mediated by BATF-IRF interactions , 2012, Nature.

[14]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[15]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[16]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[17]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[18]  S. Pileri,et al.  Pathobiology of Anaplastic Large Cell Lymphoma , 2011, Advances in hematology.

[19]  Christian Steidl,et al.  Cooperative epigenetic modulation by cancer amplicon genes. , 2010, Cancer cell.

[20]  S. Pileri,et al.  BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B‐cell lymphoma , 2010, Histopathology.

[21]  G. Inghirami,et al.  Anaplastic large cell lymphoma: one or more entities among T‐cell lymphoma? , 2009, Hematological oncology.

[22]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[23]  A. Feldman,et al.  Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas , 2008, Leukemia.

[24]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[25]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[26]  K. Basso,et al.  A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. , 2007, Cancer cell.

[27]  S. Monaco,et al.  Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c‐myc rearrangement terminating in a leukemic phase , 2007, American journal of hematology.

[28]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[29]  L. Staudt,et al.  A library of gene expression signatures to illuminate normal and pathological lymphoid biology , 2006, Immunological reviews.

[30]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[31]  Toshiki Watanabe,et al.  The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. , 2004, Cancer cell.

[32]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[33]  S. Perkins,et al.  The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. , 2002, The American journal of pathology.

[34]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[35]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[36]  S. Morris,et al.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. , 2000, Blood.

[37]  S. Pileri,et al.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.

[38]  H Stein,et al.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. , 2000, Blood.

[39]  I. Hanamura,et al.  MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies , 2000, Leukemia.

[40]  E. Cesarman,et al.  Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation. , 1994, Blood.

[41]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[42]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[43]  W. Choi,et al.  Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.

[44]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[45]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.